IL105666A - Transformed pyridines, their preparation and pharmaceutical preparations containing them - Google Patents

Transformed pyridines, their preparation and pharmaceutical preparations containing them

Info

Publication number
IL105666A
IL105666A IL10566693A IL10566693A IL105666A IL 105666 A IL105666 A IL 105666A IL 10566693 A IL10566693 A IL 10566693A IL 10566693 A IL10566693 A IL 10566693A IL 105666 A IL105666 A IL 105666A
Authority
IL
Israel
Prior art keywords
mmol
adamantyl
pyridyl
compounds
ether
Prior art date
Application number
IL10566693A
Other languages
English (en)
Hebrew (he)
Other versions
IL105666A0 (en
Original Assignee
British Tech Group
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929210489A external-priority patent/GB9210489D0/en
Priority claimed from GB929223738A external-priority patent/GB9223738D0/en
Application filed by British Tech Group filed Critical British Tech Group
Publication of IL105666A0 publication Critical patent/IL105666A0/xx
Publication of IL105666A publication Critical patent/IL105666A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Cosmetics (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL10566693A 1992-05-15 1993-05-11 Transformed pyridines, their preparation and pharmaceutical preparations containing them IL105666A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929210489A GB9210489D0 (en) 1992-05-15 1992-05-15 Heterocyclic compounds,their preparation and pharmaceutical use
GB929223738A GB9223738D0 (en) 1992-11-12 1992-11-12 Heterocyclic compounds,their preparation and pharmaceutical use

Publications (2)

Publication Number Publication Date
IL105666A0 IL105666A0 (en) 1993-09-22
IL105666A true IL105666A (en) 1999-09-22

Family

ID=26300892

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10566693A IL105666A (en) 1992-05-15 1993-05-11 Transformed pyridines, their preparation and pharmaceutical preparations containing them

Country Status (15)

Country Link
US (1) US5595995A (no)
EP (1) EP0640072B1 (no)
JP (1) JPH07506588A (no)
KR (1) KR100235976B1 (no)
AT (1) ATE195728T1 (no)
AU (1) AU673837B2 (no)
CA (1) CA2134563A1 (no)
DE (1) DE69329281T2 (no)
ES (1) ES2149817T3 (no)
IL (1) IL105666A (no)
MX (1) MX9302833A (no)
NO (1) NO302069B1 (no)
NZ (1) NZ252717A (no)
TW (1) TW223631B (no)
WO (1) WO1993023375A1 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0810223B1 (en) * 1996-05-28 2001-07-25 Pfizer Inc. Adamantyl substituted oxindoles as pharmaceutical agents
US7795468B2 (en) * 2001-01-19 2010-09-14 Chevron U.S.A. Inc. Functionalized higher diamondoids
US6864264B1 (en) * 2002-08-20 2005-03-08 Gloria L. Anderson 1-adamantyl chalcones for the treatment of proliferative disorders
JP2006160605A (ja) * 2003-07-09 2006-06-22 Nippon Kayaku Co Ltd 新規酵素阻害剤
JP2008007404A (ja) * 2004-10-08 2008-01-17 Nippon Kayaku Co Ltd 新規ピリジン誘導体
JP5368789B2 (ja) * 2005-06-17 2013-12-18 アポジー・バイオテクノロジー・コーポレイション スフィンゴシンキナーゼ阻害剤
GB0803494D0 (en) * 2008-02-26 2008-04-02 Sterix Ltd Compound

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3971797A (en) * 1973-06-15 1976-07-27 Merck & Co., Inc. S,S'-bis(pyridylmethyl)-carbonodithioates
IL83163A (en) * 1986-07-18 1991-06-10 Erba Carlo Spa Cycloalkyl-substituted 4-pyridyl derivatives,their preparation and pharmaceutical compositions containing them
DE4018260A1 (de) * 1990-06-07 1991-12-12 Basf Ag Derivate des (beta)-picolins und diese enthaltende pflanzenschutzmittel

Also Published As

Publication number Publication date
EP0640072A1 (en) 1995-03-01
DE69329281T2 (de) 2001-03-15
AU4267493A (en) 1993-12-13
ES2149817T3 (es) 2000-11-16
DE69329281D1 (de) 2000-09-28
KR100235976B1 (ko) 1999-12-15
CA2134563A1 (en) 1993-11-25
EP0640072B1 (en) 2000-08-23
WO1993023375A1 (en) 1993-11-25
NO944332L (no) 1994-11-14
TW223631B (no) 1994-05-11
US5595995A (en) 1997-01-21
MX9302833A (es) 1993-11-01
NO944332D0 (no) 1994-11-14
IL105666A0 (en) 1993-09-22
ATE195728T1 (de) 2000-09-15
NZ252717A (en) 1996-05-28
AU673837B2 (en) 1996-11-28
JPH07506588A (ja) 1995-07-20
NO302069B1 (no) 1998-01-19
KR950701620A (ko) 1995-04-28

Similar Documents

Publication Publication Date Title
US4851413A (en) Certain benzoquinones, naphthoquinones, corresponding hydroquinones which exhibit thromboxane A2 synthetase inhibition or receptor antagonism and the like
US20080221102A1 (en) Composition and methods for modulating a kinase cascade
NO312672B1 (no) Tri-substituerte fenylderivater anvendelige som PDE IV- inhibitorer, fremgangsmåte for fremstilling derav og farmasöytiskepreparater inneholdende dem
EP2155681B1 (en) Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
McDonald et al. (E)-. beta.-(Fluoromethylene)-m-tyrosine: a substrate for aromatic L-amino acid decarboxylase liberating an enzyme-activated irreversible inhibitor of monoamine oxidase
OA10694A (en) Processes and intermediates for preparing 1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine.
IL105666A (en) Transformed pyridines, their preparation and pharmaceutical preparations containing them
KR100224153B1 (ko) 6,9-비스[(2-아미노에틸)아미노]벤조[g]이소퀴놀린-5,10-디온및 이의 디말레산염의 개선된 합성 방법
US5143926A (en) Substituted pyridine-2,4-dicarboxylic acid compounds and methods of use thereof
JPS6233172A (ja) ド−パミン−β−ヒドロキシラ−ゼ抑制剤
EP0135316B1 (en) Vinyl carboxylic acid derivatives and their production
EP0094422B1 (en) Substituted pyridines
US10214496B2 (en) Azasteroidal mimics
GB2266887A (en) Substituted pyridines, their preparation and pharmaceutical use
IE63491B1 (en) New 6-fluoro-3,5-dihydroxy carboxylic acids and derivatives thereof, a process for the preparation thereof, the use thereof as medicinal agents, pharmaceutical products and intermediates
JPS61227568A (ja) 新規３‐ピリジルメチルナフチル誘導体およびそれらの製法
WO2004072037A1 (en) 2,3'-bipyridines derivatives as selective cox-2 inhibitors
CN112500345A (zh) α-氰基季碳取代四氢异喹啉化合物的合成方法
JPH0393773A (ja) 置換アミノピリジン類
JPH0366668A (ja) イミノ置換ピリジン類
CZ658590A3 (en) Aminopyridinylmethanols, aminomethylpyridinamines and their derivatives, process of their preparation, pharmaceutical composition containing such compounds and use thereof
JPH05262764A (ja) １−アリール−２−（１ｈ−１，２，４−トリアゾー ル−１−イル）エタノール誘導体
EP0594629A1 (en) Heterocyclic compounds, their preparation and pharmaceutical use
JPH0224270B2 (no)
JP2002308876A (ja) 抗菌活性を有する４−オキソキノリジン系化合物

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
RH1 Patent not in force